Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

Ngā tūemi rite

• BRIEF REPORT: Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors
  mā: Kobayashi, Susumu, me ētahi atu.
  I whakaputaina: (2013)
• BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
  mā: Costa, Daniel B, me ētahi atu.
  I whakaputaina: (2007)
• BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
  mā: Daniel B. Costa, me ētahi atu.
  I whakaputaina: (2007)
• Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer
  mā: Norihiro Yamaguchi, me ētahi atu.
  I whakaputaina: (2013)
• Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer
  mā: Yamaguchi, Norihiro, me ētahi atu.
  I whakaputaina: (2013)